Administration of Lactobacillus acidophilus FNCC 0051 in Rattus norvegicus with Type-1 Diabetes Mellitus: Glucose and Lipid Metabolism

DOI

10.2991/978-94-6463-112-8_9How to use a DOI?

Keywords

Blood glucose; Lactobacillus acidophilus; lipid profile; and type 1 diabetes mellitus

Abstract

The imbalance of gut microbiota contributes in development of type 1 diabetes melitus (DM), which is a chronic autoimmune disease characterized by immune-mediated destruction of the insulin-producing pancreatic beta (ß) cells. Around 7–12% of all diabetics were type 1 DM with the most cases occurred in children and adolescents. Lactobacillus acidophilus probiotics play important role in reducing proinflammatory cytokines (TNF-ɑ, IL-1β) and modulating the metabolism of the intestinal microbiota. This research aimed to examine the effects of L. acidophilus probiotics FNCC 0051 strain on glucose and lipid metabolism in type 1 DM Rattus norvegicus induced by streptozotocin. L. acidophilus FNCC 0051 were obtained from the collection of Center for Food and Nutrition Studies, Universitas Gadjah Mada. Bacteria were cultured on de Man-Rogosa Sharpe broth media, incubated at 37 ℃ for 48 h under carbon dioxide enriched condition, then measured the suspension doses for 1.5 × 10⁹ CFU/ml and 1.5 × 10⁸ CFU/ml. The rats were initially induced with streptozotocin, followed by administration of probiotic at the dose of 1.5 × 10⁸ and 1.5 × 10⁹ CFU/mL/day for 3 weeks. Twenty one days of L. acidophilus treatment at the dose of 1.5 × 10⁹ CFU/mL/day reduced blood glucose levels and had significant effect towards lipid profile. The mean reduction of blood glucose levels was 82.25 ± 31.12 mg/dL, and total cholesterol, triglyceride, HDL, and LDL levels mean reduction were 61.5 ± 6.24, 56.75 ± 10.69, 32.75 ± 3.86, 16.25 ± 3.40 mg/dL respectively. In conclusion, the administration of L. acidophilus probiotics at a dose of 1.5 × 10⁹ CFU/ml/day for 3 weeks improved glycemic control and lipid profile.

Copyright

© 2023 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Mardhatillah Sariyanti
AU  - Sylvia R. Putri
AU  - Tika P. Sari
AU  - Ory L. Fitkarani
AU  - Besly Sinuhaji
AU  - Nikki A. Massardi
AU  - Novriantika Lestari
AU  - Elvira Yunita
AU  - Diah A. A. Dita
PY  - 2023
DA  - 2023/03/01
TI  - Administration of Lactobacillus acidophilus FNCC 0051 in Rattus norvegicus with Type-1 Diabetes Mellitus: Glucose and Lipid Metabolism
BT  - Proceedings of the 1st International Conference for Health Research – BRIN (ICHR 2022)
PB  - Atlantis Press
SP  - 82
EP  - 91
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-112-8_9
DO  - 10.2991/978-94-6463-112-8_9
ID  - Sariyanti2023
ER  -